Sep 25,2018

Nemaura Reports Positive Zero Finger-Stick Calibration Data for SugarBEAT® Continuous Glucose Monitor

Nemaura Medical Inc. (NASDAQ: NMRD), a medical technology company developing sugarBEAT® as a non-invasive affordable and flexible Continuous Glucose Monitor (CGM) for use by people with diabetes and pre-diabetics, today announced data indicating sugarBEAT® could potentially be used as an adjunctive CGM without the need for finger-stick calibration.

PRODUCT

#cgm

View Analyst & Ambassador Comments
Go to original news
Sep 25,2018

CONTOUR®NEXT BLOOD GLUCOSE MONITORING SYSTEM TOPS THE LIST IN RECENTLY PUBLISHED INDEPENDENT ACCURACY ASSESSMENT BY DIABETES TECHNOLOGY SOCIETY

Results from a recently published comprehensive independent assessment of 18 blood glucose monitoring systems (BGMSs) have shown that the CONTOUR®NEXT BGMS finished top of the list for accuracy. The system from Ascensia Diabetes Care was the only one which had 100% of data points (311 out of 312) within the protocol limits for accuracy used by the Diabetes Technology Society (DTS) in their Blood Glucose Monitoring System Surveillance Program. Based on these results, it was one of the six systems to be awarded a 'Seal of Approval' by DTS for meeting stringent standards for accuracy in blood glucose readings. The full results were published in Diabetes Care in August 2018.

PRODUCT

#bgm

View Analyst & Ambassador Comments
Go to original news
Sep 25,2018

Tandem Diabetes Care Increases 2018 Sales Guidance and Provides Estimated Third Quarter Sales Results

Tandem Diabetes Care®, Inc. (NASDAQ: TNDM), a medical device company and manufacturer of the only touchscreen insulin pumps with continuous glucose monitoring integration, today announced that it has increased its 2018 sales guidance to $150 million to $158 million, from $140 million to $148 million, following continued strong domestic sales in the third quarter and the recent launch of the t:slim X2™ Insulin Pump in select international markets. Compared to 2017 sales of approximately $108 million, the revised guidance range represents annual sales growth of 39 percent to 47 percent.

View Analyst & Ambassador Comments
Go to original news
Sep 27,2018

Virta Health Continues Rapid Growth with New Executives, New Customers, and Industry Validation for the Virta Treatment

Virta Health, the first company with a clinically-proven treatment to safely and sustainably reverse type 2 diabetes (T2D) without the use of medications or surgery, today announced the addition of key new executives to further the reach of the Virta Treatment.

View Analyst & Ambassador Comments
Go to original news
Oct 17,2018

CVS Health to Embark on Pilot Program to Combat Diabetes in Medically Underserved Atlanta Neighborhoods

CVS Health announced today that it is embarking on a pilot project in the Tri-Cities area of Atlanta, Georgia, aimed at addressing diabetes in medically underserved communities with chronically high rates of this disease. In collaboration with Rimidi, Inc., a digital health company, and select community organizations, CVS Health will work to heighten awareness of diabetes and improve access to care among Tri-Cities area residents. Together with community organizations, Rimidi and CVS Health will enroll residents onto the Rimidi platform and engage them in the diabetes education and support services offered through the pilot.

COLLABORATION PARTNERSHIP

#institution

#rpm

View Analyst & Ambassador Comments
Go to original news
Oct 25,2018

NovioSense Announces Positive Phase 2 Clinical Trial Results and the Commencement of a Second Follow Up Study

NovioSense has demonstrated the measurement of tear glucose in diabetic patients and the correlation to blood glucose with clinically relevant accuracy. The company announced the commencement of a second, 24-patient study, to validate the use of its tear glucose sensor in type 1 diabetic patients.

CLINICAL STUDY
View Analyst & Ambassador Comments
Go to original news
Oct 03,2018

Study: Hybrid closed-loop 'artificial pancreas' system offers better glycemic control

Pediatric and adult Type 1 diabetes patients receiving a hybrid closed-loop artificial pancreas therapy demonstrated improved glucose control and lower risk of hypoglycemia compared to those managing their own glucose levels with an insulin pump and continuous glucose monitor, according to a study published today in the Lancet.

CLINICAL STUDY

#closed loop

View Analyst & Ambassador Comments
Go to original news
Oct 09,2018

With $2M seed funding, Health2047 spin out targets scalable diabetes prevention programs

Health2047, a technology innovation enterprise backed the American Medical Association, announced today the launch of its second spin out company. Called First Mile Care, the new entity will use its $2 million in seed funding to build a scalable platform for connecting people with prediabetes to coaches and demographic-appropriate behavior change guidance.

View Analyst & Ambassador Comments
Go to original news
Oct 11,2018

Pfizer shakeup yields new digital tech head, Integrity Applications' CEO steps down, and other digital health hires and departures

John Graham, the CEO and chairman of Integrity Applications, which makes the non-invasive blood sugar measurement device GlucoTrack, has stepped down from his posts for “personal reasons,” according to a release from the company. David Podwalski, Integrity’s chief commercial officer, has been appointed CEO, president, and director during the interim, while Graham will be on hand to “ensure a smooth transition with ongoing projects and relationships.

View Analyst & Ambassador Comments
Go to original news
Oct 22,2018

One Drop Appoints Brian Kemper as Vice President of Integrated Care

Diabetes-focused digital health company One Drop has tapped Brian Kemper as vice president of integrated care. Kemper comes to One Drop directly from the diabetes division at Roche, where he served as international business leader. There, he supervised Roche's deals with Dexcom, mySugr and Alere Health.

View Analyst & Ambassador Comments
Go to original news
Subscribe to DIABETES